Earlier this week, we announced the merger of SubjectWell and Clariness. It is not hyperbole when I say that this announcement is also something larger: a transformative moment for the entire life sciences ecosystem. Together, we’re not simply getting bigger, as both organizations have delivered confidence in enrollment for years. But by coming together, we’re amplifying that strength and expanding it globally and making it even more reliable, resilient, and scalable.
For years, patient recruitment has represented the single most persistent challenge in clinical research. I’ve often said that trials launch with optimism and stall in reality: Sponsors and CROs build plans, only to revise them. Patients who would benefit can’t find trials, and trials that need diversity struggle to achieve it.
This merger is our answer to that challenge.
Why this matters to sponsors
Sponsors face the impossible: rising complexity, shrinking timelines, global protocols, and increasingly precise eligibility—all while pressure mounts to deliver breakthroughs faster.
By integrating two complementary strengths—SubjectWell’s enrollment velocity and Clariness’s deep European footprint—we now offer sponsors a single partner that can:
- Deliver more reliable enrollment progress across regions and therapeutic areas
- Respond quickly as protocols evolve
- Provide deeper insights, stronger data, and clearer accountability
- Reduce operational friction through fewer handoffs and more unified execution
This is not scale for the sake of scale. It is scale that reduces uncertainty, strengthens planning, and gives sponsors a greater sense of control throughout the enrollment lifecycle.
The combined SubjectWell + Clariness platform offers something rare: confidence at global scale.
Why this matters to CROs
For CROs, patient recruitment is often the largest variable in study timelines. The industry has relied on fragmented vendors for too long, leading to inconsistency, inefficiency, and surprises.
This merger creates a recruitment partner built for how CROs operate today: global, fast‑moving, collaborative, and accountable end-to-end.
Together, we can:
- Support multi‑country studies with consistent, high‑quality execution
- Integrate more naturally into CRO workflows and systems
- Scale rapidly when protocols expand or criteria shift
- Function as a true strategic extension of CRO teams—not a transactional provider
CROs now gain a partner built around confidence, flexibility, and transparency.
Why this matters to patients
At the center of every study is a human decision, one that is often filled with hope, uncertainty, and the desire to make informed choices.
This merger strengthens our ability to reach, support, and empower patients where they are.
Together, SubjectWell and Clariness offer:
- More opportunities, patients may never have encountered
- Greater accessibility through expanded geographic reach
- More inclusive trials that reflect real‑world diversity
- Genuine human support, not just digital matching
Clinical trials only work when patients can find and trust them. This merger makes it easier, more accessible, and more equitable for millions of people.
Why this matters to the life sciences ecosystem
Clinical research does not advance in silos. It thrives when sponsors, CROs, sites, and patients are aligned around a shared mission: bringing better treatments to patients faster.
One of the ecosystem’s most persistent challenges has always been patient recruitment. When this bottleneck is reduced:
- Trials complete sooner
- Costs decrease
- Innovation accelerates
- Patients benefit earlier
Scale—when coupled with responsibility and expertise—becomes a powerful force multiplier.
What happens next
With any merger, it’s natural to wonder what changes, and what doesn’t. The most important message is this: Nothing disrupts. Everything strengthens.
We’re committed to:
- Existing teams remaining in place
- Primary points of contact staying the same
- Deliverables and commitments remaining unchanged
- Accountability staying where it belongs
As we move toward a unified organization under the Clariness brand, our priorities remain clear: continuity, quality, and trust. Our integration allows us to invest even more deeply in the people, technology, and processes that give customers greater clarity, reduced uncertainty, and strong confidence in their enrollment efforts.
We’re fully invested in:
- Reducing uncertainty in global recruitment
- Expanding access so more patients can participate
- Strengthening diversity across trials
- Innovating new ways to bridge patients, sites, and opportunities
- Accelerating progress across the entire ecosystem
At its core, this merger is not about consolidation, but about what’s possible for science, timelines, for trust, and most importantly, for patients.
And we’re only getting started.
